Phase II Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Children and Young Adults With Refractory Solid Tumors.

Trial Profile

Phase II Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Children and Young Adults With Refractory Solid Tumors.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2014

At a glance

  • Drugs Ixabepilone (Primary)
  • Indications Ewing's sarcoma; Nerve sheath neoplasms; Neuroblastoma; Neuroectodermal tumours; Osteosarcoma; Rhabdomyosarcoma; Solid tumours; Synovial sarcoma; Wilms' tumour
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Nov 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top